wsbdaily | Tue, 20 Dec 2022 03:11:27 EST Where you find Tomorrow’s Hot Stocks Yesterday!
NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
Cassava Sciences, Inc.(SAVA)
Cassava Sciences, Inc.
7801 North Capital of Texas Highway
Suite 260
Austin, TX 78731
United States
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc.... Read More
Summary & Charts
| Price | $ 38.70 | -0.87 (-2.2%) |
| Day's Range | $ 37.54 - 40.56 | |
| Previous Close | $ 39.57 | |
| Market Cap | $ 1.62B USD | |
| Short Interest % | N/A | |
| Float | N/A | |
| Outstanding | N/A |
| Exchange | NasdaqCM | |
| Industry | Biotechnology | |
| Sector | Healthcare | |
| Volume | 1.17M | |
| Avg. Volume (20 day) | 1.21M | |
| Rel. Volume (20 day) | 0.96 | |
| Rel. Volume (3 month) | 0.51 | |
| Rating | B+ | Neutral |
| DCF | N/A | Strong Buy |
| Debt/Equity | 4.31 % | Neutral |
| ROE | -25.70 % | Sell |
| ROA | -29.78 % | Neutral |
| P/E | -33.33 % | Strong Sell |
| P/B | 7.80 % | Strong Buy |
| Date | Open | High | Low | Close | Change | Volume | R. Vol. (20d) | R. Vol. (3m) | Mentions |
|---|---|---|---|---|---|---|---|---|---|
| Dec 16, 2022 | $ 38.87 | $ 40.56 | $ 37.54 | $ 38.70 | -0.87 | 1,166,392 | 0.96 | 0.51 | |
| Dec 15, 2022 | $ 43.50 | $ 44.39 | $ 39.21 | $ 39.57 | -4.55 | 1,191,394 | 0.98 | 0.53 | 3 |
| Dec 14, 2022 | $ 44.60 | $ 45.43 | $ 43.20 | $ 44.12 | -0.04 | 1,035,430 | 0.83 | 0.46 | |
| Dec 13, 2022 | $ 43.26 | $ 45.11 | $ 41.12 | $ 44.16 | +2.01 | 1,563,114 | 1.23 | 0.68 | 3 |
| Dec 12, 2022 | $ 38.80 | $ 42.56 | $ 38.07 | $ 42.15 | +3.42 | 1,852,845 | 1.31 | 0.81 | 2 |
| Dec 09, 2022 | $ 38.50 | $ 40.61 | $ 38.11 | $ 38.73 | +0.24 | 1,092,350 | 0.78 | 0.48 | 1 |
| Dec 08, 2022 | $ 36.73 | $ 39.98 | $ 35.75 | $ 38.49 | +1.58 | 1,757,770 | 1.26 | 0.77 | 2 |
| Dec 07, 2022 | $ 33.49 | $ 38.50 | $ 33.02 | $ 36.91 | +3.29 | 2,182,950 | 1.64 | 0.95 | 3 |
| Dec 06, 2022 | $ 33.74 | $ 35.28 | $ 33.12 | $ 33.62 | -0.12 | 980,064 | 0.77 | 0.42 | 1 |
| Dec 05, 2022 | $ 35.31 | $ 35.65 | $ 33.50 | $ 33.74 | -2.09 | 763,525 | 0.59 | 0.32 | |
| Dec 02, 2022 | $ 34.00 | $ 36.47 | $ 33.73 | $ 35.83 | +1.69 | 1,164,250 | 0.91 | 0.49 | 1 |
| Dec 01, 2022 | $ 34.76 | $ 35.15 | $ 33.29 | $ 34.14 | -0.69 | 700,648 | 0.54 | 0.27 | 1 |
| Nov 30, 2022 | $ 34.44 | $ 34.92 | $ 33.44 | $ 34.83 | +0.43 | 1,069,818 | 0.77 | 0.35 | 1 |
| Nov 29, 2022 | $ 33.91 | $ 36.19 | $ 33.74 | $ 34.40 | +0.49 | 957,950 | 0.70 | 0.31 | 2 |
| Nov 28, 2022 | $ 34.66 | $ 35.64 | $ 33.80 | $ 33.91 | -1.01 | 565,134 | 0.41 | 0.18 | |
| Nov 25, 2022 | $ 33.50 | $ 35.32 | $ 33.10 | $ 34.92 | +1.28 | 437,805 | 0.31 | 0.14 | |
| Nov 23, 2022 | $ 33.11 | $ 34.39 | $ 32.69 | $ 33.64 | +0.29 | 717,401 | 0.51 | 0.22 | |
| Nov 22, 2022 | $ 32.52 | $ 33.48 | $ 32.69 | $ 33.35 | +0.74 | 25,050 | 0.02 | 0.01 | |
| Nov 21, 2022 | $ 32.86 | $ 34.05 | $ 31.31 | $ 32.61 | -0.72 | 919,346 | 0.64 | 0.28 | 2 |
| Nov 18, 2022 | $ 34.80 | $ 36.50 | $ 29.50 | $ 33.33 | -1.23 | 4,145,979 | 2.93 | 1.24 | 4 |
News
The latest news about Cassava Sciences, Inc. (SAVA).
InvestorPlace | 2022-12-07 16:40:54
The completion of part of an important study is pushing Cassava Sciences (NASDAQ: SAVA ) stock up today. This clinical-stage biotech company has been volatile this month but has overall performed well.
Schaeffers Research | 2022-11-21 14:51:32
The shares of Cassava Sciences Inc (NASDAQ:SAVA) are down 3.5% at $32.17 this afternoon, after the company announced a $50 million registered direct stock offering on Friday.
InvestorPlace | 2022-11-16 10:43:13
High inflation and soaring interest rates have been the main factor behind the double-digit stock downturn so far this year, but alongside these macro factors, many stocks have plunged due to more company-specific issues—for example, corporate scandals. These scandals run the gamut, both in the type of scandal and the severity of the scandal.
Yahoo Finance | 2022-11-14 16:40:27
Yahoo Finance anchors Rachelle Akuffo, Seana Smith and Dave Briggs shares of Cassava moving higher on news that its rival Roche suffered a setback in its Alzheimer's drug research trial.
InvestorPlace | 2022-11-14 14:38:47
In today's mixed session, there are plenty of stocks making big moves. Among the biggest movers in this afternoon's session is Cassava Sciences (NASDAQ: SAVA ).
InvestorPlace | 2022-11-07 12:13:20
Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in the spotlight following the company's third-quarter earnings and a stark warning to short sellers. During Q3, the company reported a net loss of $20.3 million, equivalent to an EPS loss of 51 cents per share.
Seeking Alpha | 2022-11-02 15:27:40
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.
Earnings
| Date | Time | EPS Expected | EPS Reported | % | Revenue Expected | Revenue Reported | % |
|---|---|---|---|---|---|---|---|
| 2022-11-07 | BMO | -0.48 | -0.51 | 6.25% | -- | -- | -- |
| 2022-08-03 | BMO | -0.43 | -0.48 | 11.62% | -- | -- | -- |
| 2022-05-05 | BMO | -0.41 | -0.44 | 7.31% | -- | -- | -- |
| 2022-02-28 | BMO | -0.33 | -0.35 | 6.06% | -- | -- | -- |
| 2021-11-10 | BMO | -0.17 | -0.24 | 41.17% | -- | -- | -- |
| 2021-08-03 | BMO | -0.11 | -0.13 | 18.18% | -- | -- | -- |
| 2021-04-21 | BMO | -0.1 | -0.09 | 10% | -- | -- | -- |
| 2020-11-09 | BMO | -0.07 | -0.06 | 14.29% | -- | -- | -- |
Top Discussions
These are the top discussions over the last 24-hours that mention the SAVA stock ticker symbol.
Unusual Option Activity
Option contracts that are trading at a significantly higher volume relative to the contract's open interest. These might provide some insight into what "smart money" is doing with large volume orders.
| Type | Strike | Exp Date | DTE | Bid | Ask | Last | Volume | Open Interest | Vol/OI | IV |
|---|---|---|---|---|---|---|---|---|---|---|
| CALL | $ 35.00 | 12/08/22 | 5 | $ 1.84 | $ 2.10 | $ 1.82 | 608 | 258 | 2.36 | 0.78% |
| CALL | $ 37.00 | 12/08/22 | 5 | $ 1.01 | $ 1.29 | $ 1.05 | 119 | 84 | 1.42 | 0.83% |
| CALL | $ 39.00 | 12/08/22 | 5 | $ 0.56 | $ 0.65 | $ 0.67 | 44 | 30 | 1.47 | 0.85% |
| CALL | $ 40.00 | 12/08/22 | 5 | $ 0.42 | $ 0.52 | $ 0.49 | 415 | 191 | 2.17 | 0.89% |
| CALL | $ 55.00 | 12/08/22 | 5 | $ 0.09 | $ 0.12 | $ 0.10 | 41 | 14 | 2.93 | 1.62% |
| CALL | $ 66.00 | 12/08/22 | 5 | $ 0.04 | $ 0.11 | $ 0.08 | 62 | 25 | 2.48 | 2.05% |
| PUT | $ 31.00 | 12/08/22 | 5 | $ 0.26 | $ 0.29 | $ 0.26 | 164 | 106 | 1.55 | 0.92% |
| PUT | $ 35.00 | 12/08/22 | 5 | $ 1.14 | $ 1.28 | $ 1.19 | 231 | 42 | 5.50 | 0.81% |
| PUT | $ 37.00 | 12/08/22 | 5 | $ 2.25 | $ 2.56 | $ 2.22 | 120 | 19 | 6.32 | 0.88% |
| PUT | $ 40.00 | 12/08/22 | 5 | $ 4.55 | $ 4.90 | $ 5.04 | 15 | 11 | 1.36 | 0.95% |
| CALL | $ 65.00 | 12/15/22 | 12 | $ 0.08 | $ 0.21 | $ 0.20 | 121 | 74 | 1.64 | 1.57% |
| CALL | $ 45.00 | 12/22/22 | 19 | $ 0.76 | $ 0.87 | $ 0.78 | 123 | 59 | 2.08 | 0.97% |
| PUT | $ 24.00 | 12/22/22 | 19 | $ 0.23 | $ 0.36 | $ 0.33 | 152 | 33 | 4.61 | 1.18% |
| PUT | $ 45.00 | 05/18/23 | 166 | $ 17.00 | $ 17.95 | $ 18.30 | 41 | 27 | 1.52 | 1.16% |
Last Updated: Fri, 2 Dec 2022 21:53 EST
Failures to Deliver
Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.
Last Updated: Tue, 14 Dec 2021 12:00 EST
@wsbdaily
wsbdaily